Analysts Issue Forecasts for XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Xenon Pharmaceuticals in a note issued to investors on Tuesday, May 13th. Chardan Capital analyst R. Li expects that the biopharmaceutical company will post earnings per share of ($4.15) for the year. Chardan Capital currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Chardan Capital also issued estimates for Xenon Pharmaceuticals’ FY2026 earnings at ($2.05) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.07. The business had revenue of $7.50 million during the quarter, compared to the consensus estimate of $1.64 million. During the same period in the previous year, the business posted ($0.62) EPS.

A number of other research analysts also recently commented on XENE. Wells Fargo & Company lowered their price target on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Tuesday, May 13th. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a research report on Wednesday. They issued an “outperform” rating and a $55.00 price objective on the stock. Needham & Company LLC reduced their price objective on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, Xenon Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $54.82.

Xenon Pharmaceuticals Trading Up 2.4%

Shares of NASDAQ:XENE opened at $30.29 on Friday. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $46.00. The company has a 50-day moving average price of $34.10 and a 200 day moving average price of $37.93. The company has a market cap of $2.32 billion, a price-to-earnings ratio of -10.74 and a beta of 1.21.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. increased its position in shares of Xenon Pharmaceuticals by 177.7% during the fourth quarter. Prudential Financial Inc. now owns 39,000 shares of the biopharmaceutical company’s stock worth $1,529,000 after acquiring an additional 24,956 shares during the period. Barclays PLC increased its position in shares of Xenon Pharmaceuticals by 1,275.5% during the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $590,000 after acquiring an additional 13,903 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Xenon Pharmaceuticals by 12.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company’s stock worth $9,350,000 after acquiring an additional 26,235 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Xenon Pharmaceuticals by 38.9% during the fourth quarter. JPMorgan Chase & Co. now owns 1,356,895 shares of the biopharmaceutical company’s stock valued at $53,190,000 after purchasing an additional 380,112 shares in the last quarter. Finally, Avior Wealth Management LLC bought a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $101,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.